Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
2,316people in the Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data trial, from 2021
of them with type 2 diabetes, in this paper
Already taking injectable semaglutide, or nottheir own situation, not assigned
on injectable semaglutide
SoC medications (dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, SUs, or glucagon-like peptide-1 agonists)
Injectable semaglutide went with higher achieving glycemic control+30%
correlation, not a testthe abstract, start to end
… were 30% (risk ratio (95% CI), 1.30 (1.16 to 1.45)) more likely to …
← favours treatmentfavours comparator →
could be chanceAchieving glycemic control (A1C <7%)injectable semaglutide vs SoC medications (dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, SUs, or glucagon-like peptide-1 agonists)
RR 1.301.16–1.45
GLP-1 receptor agonistsGlycemic control
1 / 4